Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Relisted on Nasdaq

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion today said that Nasdaq has approved its application to get relisted on the exchange's Global Market.

As a result, the company's common stock began trading on the Nasdaq under ticker symbol "VRML" this morning.

Vermillion's stock had been trading on the Pink Sheets since being delisted in September 2008 for failing to meet minimum listing requirements. The Fremont, Calif.-based molecular diagnostics company soon after filed for Chapter 11 bankruptcy protection. Earlier this year, it emerged from bankruptcy protection, which had followed clearance from the US Food and Drug Administration for its OVA1 triage ovarian cancer diagnostic test.

"With today's announcement of Vermillion's relisting on Nasdaq, we expect to provide our shareholders with enhanced market maker support, more efficient access to institutional investors and investment capital, improved liquidity, and greater visibility for the company within the investment community — all part of our strategy to increase shareholder value," Sandra Gardiner, VP and CFO of Vermillion, said in a statement.

In early Tuesday trade, Vermillion's shares were up 4 percent at $12.22.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.